Scientific Updates

      Scientific Update May 2021 Issue 12

      PMI

      Published on
      May 27, 2021
      Link to more information
      Topic
      Summary

      The 12th issue of the Scientific Update features an editorial by Dr. Jorge Insuasty, our Chief Life Sciences Officer. There, he discusses what's on the horizon for research at PMI as we expand to develop products that go beyond tobacco and nicotine. Dr. Insuasty describes how these new research areas help drive our transformation, and how they complement the concept of a smoke-free future.

      Also in this issue, we take a look back at PMI events and milestones from 2020, such as the debut of our Open Science virtual event series, the historic decision by the U.S. FDA regarding our leading heated tobacco product, and more. 

      Another highlight from this issue: rather than focusing on our smoke-free product assessment, we dive into the research expertise we've developed as a result of our rigorous assessment program and how that expertise feeds back into our scientific communities.

      Flip through the pages of our latest Scientific Update to learn more.

      Related Publications

      Use of capillary aerosol generator in continuous production of controlled aerosol for non-clinical studies

      Aerosol Physics Pre-clinical Toxicology

      Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters

      Pre-clinical Toxicology

      Quantification and mapping of alkylation in the human genome reveal single nucleotide resolution precursors of mutational signatures

      Pre-clinical Toxicology

      Meta-analysis of the effects of smoking and smoking cessation on triglyceride levels

      Clinical

      An in vitro evaluation of e-vapor products: The contributions of chemical adulteration, concentration, and device power

      Pre-clinical Toxicology

      Tobacco heating system has less impact on bone metabolism than cigarette smoke

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.